UCB Buys Rights to Two Parkinson’s Disease Therapies from Synosia Therapeutics
Editorial Team
Abstract
UCB SA has acquired rights to two promising treatments for Parkinson’s disease from Synosia Therapeutics for an equity investment of USD 20 M and other payments which touch USD 725 M.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.